➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Moodys
Johnson and Johnson
Mallinckrodt
Colorcon

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 8,465,936

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,465,936
Title:Method for determining the sensitivity of patients suffering from a cancer disease to biological therapy
Abstract: The invention relates to a method for determining the sensitivity of patients suffering from a cancer disease towards targeted biological therapy based on the inhibition of signaling pathways of the members of HER family (e.g., HER-1, HER-2, HER-3 and HER-4) by determining the expression of the biomarker S6 kinase or its post-translationally modified form or of the biomarkers of the activation of S6 kinase or their post-translationally modified forms in the tumor.
Inventor(s): Hajduch; Marian (Moravsky Beroun, CZ), Dziechciarkova; Marta (Olomouc, CZ), Radova; Lenka (Otinoves, CZ), Svoboda; Marek (Syrovice, CZ)
Assignee: Univerzita Palackeho V Olomouci, Lekarska Fakulta (Olomouc, CZ) Masarykuv Onkologicky Ustav (Brno, CZ)
Application Number:12/863,517
Patent Claims:see list of patent claims

Details for Patent 8,465,936

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Univerzita Palackeho V Olomouci, Lekarska Fakulta (Olomouc, CZ) Masarykuv Onkologicky Ustav (Brno, CZ) 2028-01-25 RX Orphan search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Univerzita Palackeho V Olomouci, Lekarska Fakulta (Olomouc, CZ) Masarykuv Onkologicky Ustav (Brno, CZ) 2028-01-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Merck
Boehringer Ingelheim
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.